Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Adriana Gasca-Ruchti"'
Autor:
R.A. Soo, J.-Y. Han, U. Dafni, B.C. Cho, C.M. Yeo, E. Nadal, E. Carcereny, J. de Castro, M.A. Sala, R. Bernabé, L. Coate, M. Provencio Pulla, R. Garcia Campelo, S. Cuffe, S.M.S. Hashemi, M. Früh, B. Massuti, J. Garcia-Sanchez, M. Dómine, M. Majem, J.-M. Sanchez-Torres, C. Britschgi, M. Pless, G. Dimopoulou, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R.A. Stahel, S. Peters, Rolf Stahel, Solange Peters, Ross Soo, Ji-Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki-Voser, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne-Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Susanne Roux, Magdalena Sanchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, Martin Reist, Priska Rentsch, Sinead Cuffe, Sayed Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario Garcia Campelo, Bartomeu Massutí, Jose Garcia, Manuel Dómine, Margarita Majem, Jose Miguel Sanchez, Christian Britschgi, Miklos Pless, Chong Ming Yeo, Byoung Chul Cho
Publikováno v:
ANNALS OF ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181-192. Oxford University Press
ETOP 10-16 BOOSTER Collaborators 2022, ' A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations : the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 181-192 . https://doi.org/10.1016/j.annonc.2021.11.010
Background: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M
Autor:
Solange Peters, Enriqueta Felip, Antonio Irigoyen, Alex Martinez Marti, Claus Belka, H. Roschitzki-Voser, A.-C. Piguet, Annemarie Becker, M. Kassapian, Johan Vansteenkiste, Maarten Lambrecht, Rudolf M. Huber, Rolf A. Stahel, Urania Dafni, Nicolaus Andratschke, Dirk De Ruysscher, Adriana Gasca-Ruchti, Matthias Guckenberger, Ernest Nadal-Alforja
Publikováno v:
Journal of Clinical Oncology. 36:8510-8510
8510Background: The feasibility of combined chemo-radiotherapy (chemo-RT) and concurrent PD-1 inhibition is of high scientific interest and has shown promising results in pre-clinical models. So fa...
Autor:
Bartomeu Massuti, Robbert C. van Heemst, Javier Garde Noguera, Peter Meldgaard, Manuel Cobo Dols, Rolf A. Stahel, M. Kassapian, Urania Dafni, Santiago Ponce Aix, Ana López Martín, Irene Floriani, Christoph C. Zielinski, Oliver Gautschi, Adriana Gasca-Ruchti, Yojena Chittazhathu Kurian Kuruvilla, Solange Peters, Vanesa Gregorc, Thierry Berghmans, Egbert F. Smit, Linda Coate
Publikováno v:
Journal of Clinical Oncology. 33:8049-8049
8049 Background: Docetaxel (D) or Erlotinib (E) are registered second-line treatments for EGFR wild type NSCLC. Previous studies suggested a predictive value of the serum proteomic VeriStrat test (VS), assigning a good (VSG) or poor (VSP) classificat